Bullboard Post History

Destruction for all to see.

pela and Enhertu

Matt said that the ADC treatment Enhertu is "going to be a monster"...

RE:RE:Seeking Alpha

The author's argument is that the samples are too small to draw...

RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

Noteable, I remember clearly when you first posted that pela and CD3...

RE:RE:Buyout / evaluation scenarios with various share prices

All too true.

RE:RE:RE:RE:RE:Cmon Mat!(not Brad).....let’s see a nice positive update!

All good points inthno.

RE:RE:RE:Cmon Mat!(not Brad).....let’s see a nice positive update!

inthno, I am beginning to worry that the management and board see little...

RE:Pala offer to Melior Shareholders - See similarities w/ NCU

Hi Jay, One difference here is the kfw huge loan and the Triple Flag funding...

RE:RE:Anyone Paying Attention?

Thanks very much to Jay Griff for the summary of the share price for Pala at...

RE:RE:From Wash Post Opinions

Rest assured I read all your posts. I posted that piece as relevant and...

From Wash Post Opinions

This summer, the Food and Drug Administration approved a new drug to treat...

RE:RE:RE:Options have been issued

That is a very good question, Venture009. Maybe options can be done anytime....

RE:RE:RE:RE:RE:RE:RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding war

Adding to my previous post, They have discussed an 80 patient run in trial...

RE:RE:RE:RE:RE:RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding war

ONCY would have to apply in concert with its collaborators to get AA, which...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA's Head of CBER wants faster approvals with SE/biomarkers

Wow! that is good to see and a blast from the past. 

RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA's Head of CBER wants faster approvals with SE/biomarkers

Thanks. That is important.

RE:RE:RE:RE:RE:RE:FDA's Head of CBER wants faster approvals with SE/biomarkers

Noteable, I appreciate these valuable comments on AA potential. I would...

Validating surrogate end points

Published online 2016 May 10. doi: 10.1016/j.mayocp.2016.02.012 ...

RE:RE:RE:Canaccord Fireside Chat & pelareorep's approval in mBC

ithntdf, I heard all that as well. I do not think he would make a mistake on...

RE:RE:RE:RE:General comments, leading to Monday am N.R. Etc

Following on, One possibility is that BP really discounts the uncertainty of...